Edding Genor Details Board and Committee Structure

Genor Biopharma Holdings Limited ( (HK:6998) ) has provided an announcement.

Edding Genor Group Holdings Limited announced the current composition of its board of directors, listing two executive directors, two non-executive directors, and three independent non-executive directors. The company also detailed the membership and chairperson roles for its audit, compensation, and nomination committees, underscoring its emphasis on formalized corporate governance and board oversight structures.

The audit committee includes independent directors with one serving as chair, while the compensation and nomination committees are similarly led by independent non-executive directors. This governance setup signals an effort to align with best practices in board independence and accountability, which can bolster investor confidence and enhance regulatory and market credibility.

The most recent analyst rating on (HK:6998) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on Genor Biopharma Holdings Limited stock, see the HK:6998 Stock Forecast page.

More about Genor Biopharma Holdings Limited

Edding Genor Group Holdings Limited, listed in Hong Kong under stock code 6998, operates in the biopharmaceutical sector. The company’s board structure includes executive, non-executive, and independent non-executive directors, reflecting a typical governance framework for a publicly traded life sciences company.

Average Trading Volume: 1,284,721

Technical Sentiment Signal: Sell

Current Market Cap: HK$4.92B

For an in-depth examination of 6998 stock, go to TipRanks’ Overview page.